1-20 of 546
William G. Wierda
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV , ZAP-70, and MRD

Clinical Trials & Observations
Ekaterina Kim, Shih-Shih Chen, Mariela Sivina, Hyunsoo Hwang, Xuelin Huang, Alessandra Ferrajoli, Nitin Jain, William G. Wierda, Dominik Wodarz, Nicholas Chiorazzi, Jan A. Burger
Journal: Blood
Blood (2024) 144 (25): 2678–2681.
https://doi.org/10.1182/blood.2024025683
Published: 2024
Includes: Supplemental data
Journal Articles

Management of HCV-Infection in Pediatric Patients Undergoing HCT: A Single-Center Experience

Gennaro Pagano, Emanuela Rossitti, Fabiana Cacace, Valeria Caprioli, Maria Rosaria D'Amico, Giuseppina De Simone, Maria Simona Sabbatino, William G. Wierda, Francesco Paolo Paolo Tambaro
Journal: Blood
Blood (2024) 144 (Supplement 1): 7381.
https://doi.org/10.1182/blood-2024-200706
Published: 2024
Journal Articles

Donor-Derived NK Cell Infusion Following Haploidentical Hematopoietic Stem Cell Transplant for High-Risk and Relapsed/Refractory Pediatric Leukemia

Emanuela Rossitti, Gennaro Pagano, Fabiana Cacace, Valeria Caprioli, Maria Rosaria D'Amico, Giuseppina De Simone, Maria Simona Sabbatino, Mario Toriello, Giovanna Maisto, Roberta Penta de Vera d'aragona, Alessandra Cianflone, Peppino Mirabelli, William G. Wierda, Francesco Paolo Tambaro
Journal: Blood
Blood (2024) 144 (Supplement 1): 7189.
https://doi.org/10.1182/blood-2024-200707
Published: 2024
Journal Articles

Driving Cell Therapy in Treatment of MRD-Positive Acute Pediatric Lymphoblastic Leukemia after Allogeneic-HSCT: Blinatumomab + DLI

Emanuela Rossitti, Gennaro Pagano, Fabiana Cacace, Valeria Caprioli, Maria Rosaria D'Amico, Giuseppina De Simone, Maria Simona Sabbatino, William G. Wierda, Francesco Paolo Paolo Tambaro
Journal: Blood
Blood (2024) 144 (Supplement 1): 7190.
https://doi.org/10.1182/blood-2024-200642
Published: 2024
Journal Articles

Survival Benefits of Complete Cytogenetic Response in Patients with Newly Diagnosed Myelodysplastic Syndrome

Roberta Santos Azevedo, Hagop M. Kantarjian, Elias Jabbour, Rashmi Kanagal-Shamanna, Kelly S. Chien, Danielle Hammond, Samuel Urrutia, Carlos E. Bueso-Ramos, Keyur P. Patel, Guillermo Montalban-Bravo, Nicholas J. Short, Naval Daver, Gautam Borthakur, Tapan M. Kadia, William G. Wierda, Guillermo Garcia-Manero, Koji Sasaki
Journal: Blood
Blood (2024) 144 (Supplement 1): 6727.
https://doi.org/10.1182/blood-2024-201864
Published: 2024
Journal Articles

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Updated Follow-up of Transcend CLL 004

Tanya Siddiqi, Jordan Gauthier, Saad S. Kenderian, Danielle M. Brander, Kathleen Dorritie, Jacob D. Soumerai, Peter A. Riedell, Nirav N. Shah, Rajneesh Nath, Charalambos Andreadis, Daniel A. Ermann, Shuo Ma, Tatyana Feldman, Scott R. Solomon, Stephen J. Schuster, Sherilyn A. Tuazon, Serena K. Perna, San-San Ou, Neha Rane, Eniko Papp, Yizhe Chen, William G. Wierda
Journal: Blood
Blood (2024) 144 (Supplement 1): 4633.
https://doi.org/10.1182/blood-2024-200840
Published: 2024
Journal Articles

Time-Limited Therapy with Zanubrutinib Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia: Early Results of an Ongoing Phase II Trial

Jan A. Burger, Ekaterina Kim, Gitanjali Jayachandran, Thomas Mathew, Koji Sasaki, Yesid Alvarado Valero, Danielle Hammond, Fadi G. Haddad, William G. Wierda, Alessandra Ferrajoli
Journal: Blood
Blood (2024) 144 (Supplement 1): 4631.
https://doi.org/10.1182/blood-2024-198701
Published: 2024
Journal Articles

Gelofusine As Alternative to Dextran40 for Washing Cryopreserved Hematopoietic Stem Cell Products Prior to Infusion: Validation and Application to Clinical Practice

Stefania Nappo, Mario Toriello, Giovanna Maisto, Francesco Topo, Lucia Gallo, Giovanni Castellano, Roberta Penta de Vera d'aragona, Emanuela Rossitti, Alessandra Picardi, William G. Wierda, Francesco Paolo Tambaro
Journal: Blood
Blood (2024) 144 (Supplement 1): 2095.
https://doi.org/10.1182/blood-2024-209742
Published: 2024
Journal Articles

BRAVE: A Phase 2 Trial Evaluating the Efficacy and Safety of Venetoclax in Combination with Bruton's Tyrosine Kinase Inhibitors in Patients with First-Line Chronic Lymphocytic Leukemia

Matthew S. Davids, John M. Burke, Jennifer A. Woyach, Mina Shahkarami, Katherine Eakle, Jinnie Ko, Vivek S. Chopra, Weize Huang, Rona Farighi, Richard H. Ko, Jeff P. Sharman, William G. Wierda
Journal: Blood
Blood (2024) 144 (Supplement 1): 3257.2.
https://doi.org/10.1182/blood-2024-201555
Published: 2024
Journal Articles

Acute Lymphoblastic Leukemia in Shwachman-Diamond Syndrome: Challenges and Treatment Outcomes

Fabiana Cacace, Emanuela Rossitti, Gennaro Pagano, Valeria Caprioli, Maria Rosaria D'Amico, Giuseppina De Simone, Giovanna Giagnuolo, Rosanna Parasole, Maria Simona Sabbatino, Pio Stellato, William G. Wierda, Francesco Paolo Tambaro
Journal: Blood
Blood (2024) 144 (Supplement 1): 5710.
https://doi.org/10.1182/blood-2024-201273
Published: 2024
Journal Articles

Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10 -4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL

Mahesh Swaminathan, Philip A. Thompson, Jan A. Burger, Musa Yilmaz, Nitin Jain, Tapan M. Kadia, Lucia Masarova, Yesid Alvarado Valero, Prithviraj Bose, Alessandra Ferrajoli, Ghayas C. Issa, Steven M. Kornblau, Farhad Ravandi, Koji Sasaki, Gautam Borthakur, Kelly S. Chien, Courtney D. DiNardo, Danielle Hammond, Elias Jabbour, Guillermo Montalban-Bravo, Naveen Pemmaraju, Nicholas J. Short, Koichi Takahashi, Francesco Paolo Tambaro, Wei Qiao, Naveen Garg, Michael J. Keating, William G. Wierda
Journal: Blood
Blood (2024) 144 (Supplement 1): 1855.
https://doi.org/10.1182/blood-2024-211110
Published: 2024
Journal Articles

Atezolizumab Combined with Venetoclax and Obinutuzumab for Frontline CLL

Patrick K. Reville, Sogand Sajedi, Alessandra Ferrajoli, Jan A. Burger, Michael J. Keating, Naveen Garg, Qing Deng, Michael R. Green, Hussein A. Abbas, William G. Wierda, Nitin Jain
Journal: Blood
Blood (2024) 144 (Supplement 1): 1014.
https://doi.org/10.1182/blood-2024-206306
Published: 2024
Journal Articles

Consistently High 5.5-Year Progression-Free Survival (PFS) Rates in Patients with and without Bulky Baseline Lymphadenopathy ≥5 Cm Are Associated with High Undetectable Minimal Residual Disease (uMRD4) Rates after First-Line Treatment with Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) in the Phase 2 CAPTIVATE Study

William G. Wierda, Ryan Jacobs, Paul M Barr, John N. Allan, Tanya Siddiqi, Alessandra Tedeschi, Thomas J. Kipps, Susan M. O'Brien, Xavier C. Badoux, Andrea Visentin, Masa Lasica, Dennis A. Carney, Anna Elinder Cambrun, Javier De la Serna, Edith Szafer Glusman, Cathy Zhou, Jutta K. Neuenburg, Lynne Neumayr, Anita Szoke, James P. Dean, Paolo Ghia, Constantine S. Tam
Journal: Blood
Blood (2024) 144 (Supplement 1): 1869.
https://doi.org/10.1182/blood-2024-200936
Published: 2024
Journal Articles

A Phase II Study of Time-Limited Treatment with Acalabrutinib Plus Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

Jan A. Burger, Ekaterina Kim, Gitanjali Jayachandran, Wanda Lopez, Ghayas C. Issa, Musa Yilmaz, Mahesh Swaminathan, Jo Ishizawa, Alexandre Bazinet, Yesid Alvarado Valero, Nitin Jain, William G. Wierda, Alessandra Ferrajoli
Journal: Blood
Blood (2024) 144 (Supplement 1): 1868.
https://doi.org/10.1182/blood-2024-200331
Published: 2024
Journal Articles

Preliminary Results from a Phase 1b Study of Non-Covalent Pan-Mutant BTK Inhibitor Docirbrutinib (AS-1763) in Patients with Previously Treated B-Cell Malignancies

Nitin Jain, Catherine C. Coombs, James D'Olimpio, Nirav N. Shah, Jacqueline C. Barrientos, Seung Tae Lee, Andrew Gillis-Smith, Shuo Ma, Shirou Kirita, Masaaki Sawa, Kyoko Miyamoto, Akinori Arimura, William G. Wierda, Varsha Gandhi, Javier Pinilla-Ibarz
Journal: Blood
Blood (2024) 144 (Supplement 1): 1866.
https://doi.org/10.1182/blood-2024-208549
Published: 2024
Journal Articles

Venetian: A Phase 2b/3 Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) and Optimize Initiation of Venetoclax (Ven) in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)

William G. Wierda, Matthew S. Davids, Jeff P. Sharman, Nilanjan Ghosh, Yang Feng, Mary Jean Fusco, Jacqueline Hilger-Rolfe, Chen Qian, Wendy J. Sinai, Sophie Wimberley, John F. Seymour
Journal: Blood
Blood (2024) 144 (Supplement 1): 6784.
https://doi.org/10.1182/blood-2024-207716
Published: 2024
Journal Articles

Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study

William G. Wierda, Kathleen Dorritie, Jordan Gauthier, Rajneesh Nath, Thomas J. Kipps, Peter A. Riedell, Herbert A. Eradat, Saad S. Kenderian, Mohamed A. Kharfan-Dabaja, Nirav N. Shah, Scott R. Solomon, Daniel A. Ermann, Jon E. Arnason, Abhinav Deol, Tatyana Feldman, Charalambos Andreadis, Monalisa Ghosh, Shuo Ma, Stephen J. Schuster, Usama Gergis, Julie M. Vose, Jacob D. Soumerai, Koen van Besien, Sherilyn A. Tuazon, Serena K. Perna, San-San Ou, Neha Rane, Eniko Papp, Yizhe Chen, Tanya Siddiqi
Journal: Blood
Blood (2024) 144 (Supplement 1): 887.
https://doi.org/10.1182/blood-2024-200339
Published: 2024
Journal Articles

Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Nitin Jain, Alessandra Ferrajoli, Mahesh Swaminathan, Patrick K. Reville, Jan A. Burger, Vanthana Bharathi, Himachandana Atluri, Hua-Jay J Cherng, Alex Bataller, Elias Jabbour, Tapan M. Kadia, Gautam Borthakur, Koichi Takahashi, Kelly S. Chien, Musa Yilmaz, Naveen Pemmaraju, Naval Daver, Fadi G. Haddad, Yesid Alvarado Valero, Jo Ishizawa, Guillermo Montalban-Bravo, Naveen Garg, Hyunsoo Hwang, Wei Qiao, Cameron Garcia, Anna Evangelio, Ana Ayala, Deepa Sampath, Varsha Gandhi, Michael J. Keating, Hagop M. Kantarjian, William G. Wierda
Journal: Blood
Blood (2024) 144 (Supplement 1): 1011.
https://doi.org/10.1182/blood-2024-211454
Published: 2024
Journal Articles

Protein Degrader WH25244 Eliminates Venetoclax Resistance Factors: Mutant or Hyperphosphorylated BCL2, and BCL-XL

Daisy Y. Diaz Rohena, Andrew D. Mitchell, Jing Wang, Stephanie Chamberlain, Chaomei Liu, John R. Sanchez, II, Charmelle D. Williams, Trisha K. Wathan, Bailey Slawin, Kevin Bowman, Yaxia Yuan, Peiyi Zhang, Wanyi Hu, Guangrong Zheng, William G. Wierda, Nitin Jain, Matthew S. Davids, Daohong Zhou, Jennifer A. Woyach, Deepa Sampath
Journal: Blood
Blood (2024) 144 (Supplement 1): 2786.
https://doi.org/10.1182/blood-2024-208159
Published: 2024
Journal Articles

Predictors for Time-to-First-Treatment in Patients with Del(17p) and/or TP53 -Mutated Chronic Lymphocytic Leukemia

Anjali Lankford, Mahesh Swaminathan, Amrit S. Gonugunta, Himachandana Atluri, Hannah Goulart, Koji Sasaki, Guilin Tang, Rashmi Kanagal-Shamanna, Jan A. Burger, Alessandra Ferrajoli, Hagop Kantarjian, William G. Wierda, Nitin Jain
Journal: Blood
Blood (2024) 144 (Supplement 1): 3246.
https://doi.org/10.1182/blood-2024-208974
Published: 2024